Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss

Neuro Oncol. 2018 Jan 22;20(2):289-291. doi: 10.1093/neuonc/nox217.

Authors

Morgan L Prust^{1

2}, Kourosh Jafari-Khouzani², Jayashree Kalpathy-Cramer², Pavlina Polaskova², Tracy T Batchelor¹, Elizabeth R Gerstner¹, Jorg Dietrich¹

Affiliations

¹ Department of Neurology, Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
² Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

No abstract available

Keywords: brain atrophy; chemoradiation; glioblastoma; neuroimaging; neurotoxicity.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Chemoradiotherapy / adverse effects
Female
Glioblastoma / drug therapy*
Glioblastoma / pathology
Glioblastoma / radiotherapy*
Gray Matter / drug effects
Gray Matter / pathology*
Humans
Magnetic Resonance Imaging / methods
Male
Middle Aged
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
White Matter / drug effects
White Matter / pathology*

Substances

Vascular Endothelial Growth Factor A

Grants and funding